Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Vera Therapeutics Inc shares valued at $4,369,676 were purchased by ENRIGHT PATRICK G on Jun 23 ’25. At $20.87 per share, ENRIGHT PATRICK G acquired 209,393 shares. The insider’s holdings grew to 3,569,522 shares worth approximately $68.71 million following the completion of this transaction.
Also, ENRIGHT PATRICK G purchased 40,607 shares, netting a total of over 907,635 in proceeds. Following the buying of shares at $22.35 each, the insider now holds 3,596,593 shares.
Before that, Fordyce Marshall had sold 10,613 shares from its account. In a trade valued at $296,032, the PRESIDENT AND CEO traded Vera Therapeutics Inc shares for $27.89 each. Upon closing the transaction, the insider’s holdings decreased to 10,613 shares, worth approximately $4.11 million.
As published in a research note from Wolfe Research on August 04, 2025, Vera Therapeutics Inc [VERA] has been rated down from an Outperform to a Peer perform. As of February 04, 2025, Wolfe Research has initiated its “an Outperform” rating for VERA. Earlier on January 28, 2025, Goldman initiated its rating. Their recommendation was “a Buy” for VERA stock.
Analyzing VERA Stock Performance
On last trading session, Vera Therapeutics Inc [NASDAQ: VERA] plunged -6.73% to $19.25. The stock’s lowest price that day was $19.19, but it reached a high of $20.29 in the same session. During the last five days, there has been a drop of approximately -8.72%. Over the course of the year, Vera Therapeutics Inc shares have dropped approximately -48.52%.
Is Vera Therapeutics Inc subject to short interest?
Stocks of Vera Therapeutics Inc saw a sharp steep in short interest on 2025-07-15 dropping by -1.32 million shares to 8.24 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 9.56 million shares. A decline of -16.04% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.26 of the overall float, the days-to-cover ratio (short ratio) decline to 6.26.
Which companies own the most shares of Vera Therapeutics Inc (VERA)?
In terms of Vera Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 65 in the next 12 months, up nearly 214.92% from the previous closing price of $20.64. Analysts anticipate Vera Therapeutics Inc stock to reach 65 by 2025, with the lowest price target being 65. In spite of this, 5 analysts ranked Vera Therapeutics Inc stock as Buy at the end of 2025. On November 21, 2024, Wells Fargo assigned a price target of “an Overweight” to the stock and initiated coverage with a $70.
